Journal article
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
AJ Frew, RW Johnstone, JE Bolden
Cancer Letters | Published : 2009
Abstract
Histone deacetylase inhibitors (HDACi) are anti-cancer drugs that have moved rapidly through clinical development and in 2006 vorinostat (SAHA, Zolinza) was given FDA approval for the treatment of cutaneous T cell lymphoma. Class I, II and IV HDACs that are targets for these compounds deacetylate histone proteins, resulting in chromatin remodelling and altered gene transcription. In addition, numerous non-histone proteins are modified by acetylation and the inhibition of HDAC activity can therefore affect various molecular processes. This broad effect on protein function may account for the pleiotropic anti-tumor responses elicited by HDACi that include induction of tumor cell apoptosis, cel..
View full abstractGrants
Funding Acknowledgements
We apologise to those whose work was not cited or discussed due to space limitations. We thank members of the Johnstone laboratory for helpful discussions. Ricky Johnstone is a Pfizer Australia Research Fellow and is supported by the National Health and Medical Research Council of Australia, the Cancer Council Victoria, the Leukaemia Foundation of Australia and by research grants from Novartis and Merck. Ailsa Frew and Jessica Bolden are supported by The Cancer Research Institute Predoctoral Emphasis Pathway in Tumor Immunology.